Research Article

Clinical Efficacy of Osimertinib in Patients with Advanced Non-Small Cell Lung Cancer and Its Effect on Serum CEA and VEGF Expression

Huanyuan Wang,1 Xiangwu Zhou,2 Zhaozhen Wang,3 Tianzhu Lu,4 Baoliang Li,5 and Sicong Jiang6

1Department of Thoracic Surgery, Jiangxi Cancer Hospital of Nanchang University, Nanchang 330029, China
2Department of Thoracic Surgery, Medical College of Nanchang University, Nanchang 330006, China
3Department of Clinical Medicine, Jiangxi Health Vocational College of China, Nanchang, Jiangxi, China
4Department of Radiation Oncology, Jiangxi Cancer Hospital of Nanchang University, Nanchang 330029, China
5Guangdong Provincial Key Laboratory of Orthopedics and Traumatology, Orthopaedic Research Institute/Department of Spinal Surgery, The First Affiliated Hospital of Sun Yat-Sen University, Guangzhou 510080, China
6Division of Thoracic and Endocrine Surgery, University Hospitals and University of Geneva, Geneva 1211, Geneva 4, Switzerland

Correspondence should be addressed to Sicong Jiang; 18270200970@163.com

Received 28 February 2022; Revised 22 March 2022; Accepted 26 April 2022; Published 25 May 2022

Academic Editor: Zhaqi Dong

Copyright © 2022 Huanyuan Wang et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Objective. To assess the clinical efficacy of osimertinib in patients with advanced non-small cell lung cancer and its effect on serum carcinoembryonic antigen (CEA) and vascular endothelial growth factor (VEGF) expression. Methods. Between July 2018 and January 2020, 80 patients with advanced non-small cell lung cancer were assessed for eligibility and recruited. The patients were assigned at a ratio of 1:1 to receive either the PC regimen (pemetrexed + cisplatin) (conventional group) or osimertinib (experimental group). The primary endpoint was the clinical efficacy, and the secondary endpoints were the adverse events, expression of serum CEA and VEGF, and 2-year survival. Results. Osimertinib was associated with a significantly higher response rate and disease control rate versus pemetrexed plus cisplatin (P < 0.05). Osimertinib resulted in a significantly lower incidence of adverse events versus the PC regimen (P < 0.05). Patients given osimertinib had significantly lower levels of CEA and VEGF versus those given pemetrexed plus cisplatin (P < 0.05). Osimertinib was associated with a significantly higher 1-year and 2-year survival rate versus pemetrexed plus cisplatin Conclusion. Osimertinib could inhibit the expression of serum CEA and VEGF in patients with advanced non-small cell lung cancer and reduce the adverse events with significant efficacy, so it is worthy of clinical promotion and application.

1. Introduction

Lung cancer is currently the most prevalent malignancy with the highest mortality rate worldwide, among which non-small cell lung cancer (NSCLC) accounts for approximately 78% [1]. Due to the absence of specific signs and symptoms in the early stages of NSCLC, about 70% of cases have progressed to an advanced stage at the time of diagnosis, where patients showed an excessively poor 5-year survival [2]. The Japanese Cancer Institute recommends chemotherapy treatment for patients with advanced NSCLC without surgical indication, of which PC regimen (pemetrexed + cisplatin) is well-recognized [3] and can efficiently promote apoptosis of tumor cells. However, numerous clinical studies have shown that the PC regimen (pemetrexed + cisplatin) is associated with considerable adverse events and suppression of immune function [4], which is detrimental to the functional recovery of patients [5]. It has
been confirmed that epidermal growth factor receptor gene mutations are present in 35%–45% of NSCLC patients in China, and the 1st and 2nd generation EGFR complex kinase inhibitors are available for targeted treatment of NSCLC, which substantially prolongs the survival of patients [6]. Nevertheless, its acquired resistance results in disease progression after 6–12 months of treatment, and about 58% of all drug resistance is attributed to T790M mutations [7]. Osimertinib belongs to the 3rd generation EGFR-TKIs and is the only drug currently available for the treatment of NSCLC with EGFR-T790M mutation-positive and resistance to 1st generation EGFR-TKIs [8]. Relevant animal experiments have revealed that osimertinib could inhibit tumor growth, improve immunity, and prolong the survival of NSCLC mice [9]. There are few relevant trials on the application of osimertinib in clinical practice in China. Accordingly, 80 patients with advanced non-small cell lung cancer were recruited to assess the clinical efficacy of osimertinib in patients with advanced non-small cell lung cancer and its effect on serum CEA and VEGF expression to provide a reference basis for clinical practice. The novelty of this study is the use of osimertinib, which is a 3rd generation EGFR-TKIs, and is the only current treatment for EGFR-T790M mutation-positive NSCLC that is resistant to 1st generation EGFR-TKIs.

2. Materials and Methods

2.1. Baseline Data. Between July 2018 and January 2020, 80 patients with advanced non-small cell lung cancer were assessed for eligibility and recruited. The patients were assigned to either a conventional group (n = 40) or an experimental group (n = 40). Patients in the conventional group were aged 53–82 years, and those in the experimental group were aged 54–82 years. The studies involving human participants were reviewed and approved by our hospital, no. JX3971. The patients provided their written informed consent to participate in this study.

2.2. Inclusion and Exclusion Criteria. Inclusion criteria are as follows: (1) all patients were diagnosed by MRI imaging and pathology, met the diagnostic criteria for non-small cell lung cancer as per the Clinical Practice Guidelines for Non-Small Cell Lung Cancer, were diagnosed as stage IIIA, IIIB, and IV as per the international lung cancer staging criteria, with T790M mutation by genetic testing, or received osimertinib after disease progression of first-line/multiline therapy (after application of the first generation of EGFR-TKIs); (2) with an expected survival of >3 months and a Karnofsky performance status (KPS) score of >60 points; (3) without symptoms of systemic failure. Exclusion criteria are as follows: (1) patients with severe liver and kidney injury, cardiovascular diseases, and autoimmune diseases; (2) with extensive systemic metastases and cachexia; (3) with poor compliance, intolerance of treatment or withdrawal of consent; (4) with severe psychiatric diseases; (5) with other targeted drugs against T790M mutation before the use of osimertinib.

2.3. Methods. The conventional group was given the conventional PC regimen chemotherapy: pemetrexed (Nanjing Pharmaceutical Factory Co. Ltd., National Drug Administration H20080177, specification 0.5 g) 500 mg/m² was given intravenously on day 1. Cisplatin (Guangdong Lingnan Pharmaceutical Co. Ltd., State Drug quantification H20183341, specification 10 mL:10 mg) 20 mg/m² was given 30 min after the pemetrexed administration, days 1–5. The experimental group was given oral osimertinib (Sweden-AstraZeneca AB, State Drug Administration J20180027, specification 80 mg), at a dose of 80 mg/d. One course of treatment was 21 d. Both groups of patients were treated for 4 courses.

2.4. Endpoints. (1) Efficacy assessment criteria: at the 4th week after treatment, short-term efficacy was evaluated with reference to the efficacy assessment criteria of solid tumors. Complete response (CR): patients’ lesions disappeared and lasted for at least 4 weeks; partial response (PR): the patient’s tumor volume was reduced by > 50% and lasted for at least 4 weeks; stable disease (SD): the patient’s tumor volume increased by 25% or reduced by < 50%; progressive disease (PD): the patient’s tumor volume increased by > 25%. Treatment response rate (RR) = CR + PR; disease control rate (DCR) = CR + PR + SD. (2) Adverse events: adverse events included white blood cell decline, liver function damage, rash, pruritus, and neutropenia, and the incidence of adverse events of calculated. (3) Serum indices: before and after treatment, 5 mL of fasting venous blood was collected from two groups of patients, centrifuged at 3000 r/min for 10 min, and the serum was collected to determine the levels of carcinoembryonic antigen (CEA) and vascular endothelial growth factor (VEGF) by the enzyme-linked immunoassay, with the kits provided by Beijing Wantai Biological Pharmaceutical Co. The normal reference value of CEA was ≤ 5.90 μg/L, and the normal reference value of VEGF was < 127 pg/mL.

2.5. Statistical Analysis. SPSS 21.0 was used for data analyses. The measurement data were expressed as (X ± s) and processed using the independent samples t-test. The count data were expressed as the number of cases (rate) and processed using the chi-square test. Survival analysis was performed using Kaplan-Meier analysis. Differences were considered statistically significant at P < 0.05.

3. Results

3.1. Baseline Data. The two groups showed similar baseline data (P > 0.05). (Table 1).

3.2. Clinical Efficacy. Osimertinib was associated with a significantly higher response rate and disease control rate versus pemetrexed plus cisplatin (P < 0.05) (Table 2).
3.3. Adverse Events. Osimertinib resulted in a significantly lower incidence of adverse events versus the PC regimen (P < 0.05) (Table 3).

3.4. Serum CEA and VEGF. Patients given osimertinib had significantly lower levels of CEA and VEGF versus those given pemetrexed plus cisplatin (P < 0.05) (Table 4).

3.5. 2-Year Survival. The two groups had similar 6-month survival (94.29% vs. 91.43%) (X² = 0.235, P = 0.671). Patients receiving osimertinib showed a higher 1-year and 2-year survival (77.14% and 54.29%) versus those given pemetrexed plus cisplatin (60.00% and 34.29%) (X² = 4.058, P = 0.044, X² = 4.644, P = 0.031).

4. Discussion

In recent years, the incidence of non-small cell lung cancer has shown an increasing trend [10], and clinical data show that about 50% of cases with NSCLC are over 60 years old, and nearly 30% of patients are over 70 years old [11]. Elderly patients are mostly accompanied by underlying diseases, and the lack of typical symptomatic manifestations in the early stage of NSCLC usually results in an advanced stage of disease by the time patients develop symptoms such as irritating dry cough, chest tightness, chest pain, and hoarseness [12]. Clinically, surgery is considered little effective for advanced NSCLC, so chemotherapy and radiotherapy are the current mainstays of treatment [13]. PC regimen (pemetrexed + cisplatin) is the treatment of choice for advanced lung cancer, as it can effectively suppress tumor development. However, clinical studies have revealed the association of the PC regimen with impaired immune function, significant adverse events, and poor prognosis [14]. Thus, there exists a need to explore more efficient treatment protocols [15]. Molecular targeted therapy mainly refers to the use of targeted drugs to act on key molecules in the signaling pathways to inhibit the proliferation and invasion of malignant tumors with high safety [16]. Osimertinib is the latest generation targeted drug that acts on the EGFR signaling pathway and competitively binds to EGFR to inhibit complex kinase activation, thereby blocking the EGFR signaling pathway, which consequently inhibits tumor cell proliferation and metastasis and promotes tumor cell apoptosis [17]. It is clinically available in patients with Troche. A related study by Schmid et al. evaluated the efficacy of osimertinib in advanced non-small cell lung cancer, in which the disease control rate was 85% in 27 patients with confirmed positive EGFR T790M mutations, and further analysis of the efficacy of osimertinib in patients with T790M-positive brain metastases revealed no significant difference in the comparison with those without brain metastases, indicating that osimertinib is equally effective in patients with advanced non-small cell lung cancer with brain metastases [18]. In the present study, osimertinib was associated with a significantly higher response rate and disease control rate versus pemetrexed plus cisplatin, which is consistent with the previous research results, suggesting a promising clinical efficacy of osimertinib for patients with non-small cell lung cancer. Moreover, osimertinib resulted

| Table 1: Comparison of baseline data (n (%)). |
|---------------------------------------------|
|                                            |
| Conventional group (n = 40) | Experimental group (n = 40) | t or \( x^2 \) | P value |
| Gender                                      |
| Male                                        |
| 24                                          |
| 26                                          |
| Mean age (year)                             |
| 66.87 ± 5.34                                |
| 66.93 ± 5.36                                |
| Smoking                                     |
| Yes                                         |
| 27                                          |
| 28                                          |
| No                                          |
| 13                                          |
| 12                                          |
| TNM staging                                 |
| IIIA                                        |
| 18                                          |
| 20                                          |
| IIIB                                        |
| 13                                          |
| 12                                          |
| IV                                          |
| 9                                           |
| 8                                           |
| Pathological type                           |
| Adenocarcinoma                              |
| 37                                          |
| 38                                          |
| Adenosquamous carcinoma                     |
| 3                                           |
| 2                                           |

| Table 2: Comparison of clinical efficacy (n (%)). |
|---------------------------------------------|
|                                            |
| Conventional group (n = 40) | Experimental group (n = 40) | \( x^2 \) | P value |
| CR                           |
| 8                            |
| 13                           |
| PR                           |
| 11                           |
| 20                           |
| SD                           |
| 7                            |
| 3                            |
| PD                           |
| 14                           |
| 4                            |
| RR                           |
| 19 (48%)                     |
| 33 (83%)                     |
| DCR                          |
| 26 (65%)                     |
| 36 (90%)                     |
in a significantly lower incidence of adverse events versus the PC regimen, indicating a higher safety profile of osimertinib [19]. Clinical studies have shown that patients with non-small cell lung cancer have higher than normal levels of CEA, the expression of which can visually reflect tumor cell activity, and that VEGF, a heparin-binding growth factor specific for vascular endothelial cells, can induce neovascularization in patients. The results of Wu et al. showed that tumor tissue growth requires neovascularization to provide oxygen and nutrients for maintenance [20]. Herein, the patients given osimertinib had significantly lower levels of CEA and VEGF versus those given pemetrexed plus cisplatin, indicating that osimertinib can effectively down-regulate serum CEA and VEGF levels in patients with non-small cell lung cancer, which thus mirrors its inhibition of tumor cell growth or metastasis. The reason for this may be attributed to the inhibition of EGFR-T790M mutation-positive or cancer cell spread by osimertinib [21]. VEGF is a vascular endothelial cell-specific heparin-binding growth factor that induces vascular neovascularization in vivo. Studies have shown that tumor tissue growth must be maintained by neovascularization to provide oxygen and nutrients. Therefore, monitoring VEGF expression can visually reflect the development of tumor tissue. Osimertinib has been shown to be effective in the short- and long-term treatment of NSCLC, with suppression of CEA and VEGF expression, prolonged survival, and tolerable side effects. However, it is worth noting that this regimen still exhibits a certain incidence of failure in the treatment of advanced NSCLC due to resistance mechanisms such as C797S mutation, activation of multiple bypass pathways, and epithelial-mesenchymal transition, so a more effective treatment regimen remains to be explored. The limitation of this study is the absence of drug resistance research, and more relevant data will be obtained in the future during long-term follow-up to obtain more detailed data. Compound Kushen injection is extracted and refined from bitter ginseng and white tulip, rich in alkaloids such as bitter ginseng alkaloids and oxidized bitter ginseng alkaloids, which are widely used in antitumor, anti-hepatitis B virus, anti-inflammatory, and antiallergy applications. As bitter ginseng alkaloids can inhibit the proliferation of lung cancer cells and induce their apoptosis, Kushen injection can be introduced to the treatment of NSCLC to explore more effective treatment regimens.

5. Conclusion

Osimertinib could inhibit the expression of serum CEA and VEGF in patients with advanced non-small cell lung cancer and reduce the adverse events with significant efficacy, so it is worthy of clinical promotion and application.

Data Availability

The datasets used during the present study are available from the corresponding author upon reasonable request.

Conflicts of Interest

The authors declare that they have no conflicts of interest.

Acknowledgments

This research was supported by a grant from Jiangxi Administration of Traditional Chinese Medicine, funded by the China government (Project number: 2021B704).

References

[1] E. B. Garon, M. D. Hellmann, N. A. Rizvi et al., “Five-year overall survival for patients with advanced non–small-cell lung cancer treated with pembrolizumab: results from the phase I KEYNOTE-001 study,” Journal of Clinical Oncology, vol. 37, no. 28, pp. 2518–2527, 2019.

[2] J. P. Gregg, T. Li, and K. Y. Yoneda, “Molecular testing strategies in non-small cell lung cancer: optimizing the diagnostic journey,” Translational Lung Cancer Research, vol. 8, no. 3, pp. 286–301, 2019.
[3] R. L. McDermott, A. Mihai, M. Dunne et al., “Stereotactic ablative radiation therapy for large (≥5 cm) non-small cell lung carcinoma,” *Clinical Oncology*, vol. 33, no. 5, pp. 292–299, 2021.

[4] U. Nestle, T. Schimek-Jasch, S. Kremp et al., “Imaging-based target volume reduction in chemoradiotherapy for locally advanced non-small-cell lung cancer (PET-Plan): a multicentre, open-label, randomised, controlled trial,” *The Lancet Oncology*, vol. 21, no. 4, pp. 581–592, 2020.

[5] F. Huang, Y. Cao, C. Wang et al., “PNMA5 promotes bone metastasis of non-small-cell lung cancer as a target of BMP2 signaling,” *Frontiers in Cell and Developmental Biology*, vol. 9, Article ID 678931, 2021.

[6] Y. Cheng, Y. He, W. Li et al., “Osimertinib versus comparator EGFR tki as first-line treatment for EGFR-mutated advanced NSCLC: FLAURA China, A randomized study,” *Targeted Oncology*, vol. 16, no. 2, pp. 165–176, 2021.

[7] J. H. Cho, S. H. Lim, H. J. An et al., “Osimertinib for patients with non-small-cell lung cancer harboring uncommon EGFR mutations: a multicenter, open-label, phase II trial (KCSG-LU15-09),” *Journal of Clinical Oncology*, vol. 38, no. 5, pp. 488–495, 2020.

[8] A. Leonetti, S. Sharma, R. Minari, P. Perego, E. Giovannetti, and M. Tiseo, “Resistance mechanisms to osimertinib in EGFR-mutated non-small cell lung cancer,” *British Journal of Cancer*, vol. 121, no. 9, pp. 725–737, 2019.

[9] M. Nagasaka, V. W. Zhu, S. M. Lim, M. Greco, F. Wu, and S. H. I. Ou, “Beyond osimertinib: the development of third-generation EGFR tyrosine kinase inhibitors for advanced EGFR+ NSCLC,” *Journal of Thoracic Oncology*, vol. 16, no. 5, pp. 740–763, 2021.

[10] V. Prakash, S. Singh, R. Kant et al., “Differential diagnosis of non-small cell lung carcinoma by circulating microRNA,” *Journal of Cancer Research and Therapeutics*, vol. 16, no. 1, pp. 127–131, 2020.

[11] D. Kazdal, “Fusion-positive non-small cell lung carcinoma: biological principles, clinical practice, and diagnostic implications,” *Genes Chromosomes Cancer*, 2022.

[12] C. Le Pechoux, N. Pourel, F. Barlesi et al., “Postoperative radiotherapy versus no postoperative radiotherapy in patients with completely resected non-small-cell lung cancer and proven mediastinal N2 involvement (Lung ART): an open-label, randomised, phase 3 trial,” *The Lancet Oncology*, vol. 23, no. 1, pp. 104–114, 2022.

[13] S. Lu, I. Casarini, T. Kato et al., “Osimertinib maintenance after definitive chemoradiation in patients with unresectable EGFR mutation positive stage III non-small-cell lung cancer: LAURA trial in progress,” *Clinical Lung Cancer*, vol. 22, no. 4, pp. 371–375, 2021.

[14] L. Zhang, P. Qiang, J. Yu et al., “Identification of compound CA-5f as a novel late-stage autophagy inhibitor with potent anti-tumor effect against non-small cell lung cancer,” *Autophagy*, vol. 15, no. 3, pp. 391–406, 2019.

[15] Y. Ohe, F. Imamura, N. Nogami et al., “Osimertinib versus standard-of-care EGFR-TKI as first-line treatment for EGFRm advanced NSCLC: FLAURA Japanese subset,” *Japanese Journal of Clinical Oncology*, vol. 49, no. 1, pp. 29–36, 2019.

[16] V. A. Papadimitrakopoulou, T. Mok, J. Y. Han et al., “Osimertinib versus platinum-pemetrexed for patients with EGFR T790M advanced NSCLC and progression on a prior EGFR tyrosine kinase inhibitor: AURA3 overall survival analysis,” *Annals of Oncology*, vol. 31, no. 11, pp. 1536–1544, 2020.